UBC Medical Indonesia Valuation

Is LABS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LABS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LABS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LABS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LABS?

Key metric: As LABS is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LABS. This is calculated by dividing LABS's market cap by their current revenue.
What is LABS's PS Ratio?
PS Ratio	3.8x
Sales	Rp136.70b
Market Cap	Rp513.50b

LABS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.9x
Enterprise Value/EBITDA	34.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does LABS's PS Ratio compare to its peers?

The above table shows the PS ratio for LABS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.6x
PEVE PT. Penta Valent	0.2x	n/a	Rp430.8b
IRRA Itama Ranoraya	0.6x	n/a	Rp630.3b
SDPC Millennium Pharmacon International	0.06x	n/a	Rp220.4b
MMIX Multi Medika Internasional	1.5x	n/a	Rp196.8b
LABS UBC Medical Indonesia	3.8x	n/a	Rp513.5b

Price-To-Sales vs Peers: LABS is expensive based on its Price-To-Sales Ratio (3.8x) compared to the peer average (0.6x).

Price to Sales Ratio vs Industry

How does LABS's PS Ratio compare vs other companies in the ID Healthcare Industry?

4 Companies	Price / Sales	Estimated Growth	Market Cap
EPMT Enseval Putera Megatrading	0.2x	n/a	US$407.84m
PEVE PT. Penta Valent	0.2x	n/a	US$27.14m
SDPC Millennium Pharmacon International	0.06x	n/a	US$13.89m
ZBRA Dosni Roha Indonesia	0.2x	n/a	US$12.34m

No more companies available in this PS range

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: LABS is expensive based on its Price-To-Sales Ratio (3.8x) compared to the ID Healthcare industry average (2.1x).

Price to Sales Ratio vs Fair Ratio

What is LABS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LABS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LABS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.